Olaparib Clinical Trials Uk, . Last reviewed: 12 February 2025 The EU Clinical Trials Register currently displays 44394 clinical trials with a EudraCT protocol, of which 7406 are clinical trials conducted with subjects less than 18 years old. The OlympiA trial showed that 1 year of adjuvant olaparib can meaningfully reduce recurrence risk and prevent progression to metastatic This is a retrospective observational medical records review study of BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting in This is a retrospective observational medical records review study of BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting in This is a retrospective, observational medical records review study of patients with BRCA-mutated advanced ovarian cancer who received maintenance olaparib as a first line treatment in France, Italy Clinical trials of olaparib, led by researchers from the ICR and the Royal Marsden NHS foundation trust, then showed that olaparib was effective for patients with a range of cancers In this clinical trial (TOPARP-A, Trial of PARP Inhibition in Prostate Cancer), we treated men with metastatic, castration-resistant prostate cancer Olaparib is an oral poly (adenosine diphosphate–ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a BRCA Preclinical studies and results of a phase 2 trial of abiraterone and olaparib suggest a combined antitumor effect when the poly (adenosine We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy of olaparib as maintenance therapy in patients The randomized, double-blind OlympiA trial compared 1 year of the oral poly (adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to PROpel, a phase 3 clinical trial, looked at whether combining olaparib with abiraterone delays the progression of patients’ cancer compared with This trial is looking at olaparib and radiotherapy for people with a type of brain tumour called a glioblastoma who cannot have standard treatment. The OCTOVA trial has demonstrated that the combination of olaparib and cediranib has promising activity in platinum-resistant patients with an improved median PFS (5. Learn more about the OlympiA clinical trial. The men taking part had cancer that got worse despite hormone therapy and chemotherapy To evaluate the antitumour activity of olaparib against metastatic castration-resistant prostate cancer, we designed TOPARP, an adaptive programme of serial phase 2 clinical trials Details This trial looked at olaparib for men with prostate cancer that had spread elsewhere in the body. The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician’s choice of The phase 3 PROpel trial efficacy and safety results show clinical benefits and a manageable safety profile of olaparib plus abiraterone versus a The trial team wanted to find the best dose of olaparib to treat leukaemia and lymphoma and if it might help people live longer. 4 months) AstraZeneca website for UK healthcare professionals only. The men taking part had cancer that got worse despite Analysis of PROfound trial end points in patients with BRCA-altered mCRPC whose disease had progressed on previous NHA shows consistent This trial compared olaparib and chemotherapy to chemotherapy alone for triple negative breast cancer or breast cancer with a change in the BRCA gene. Conclusions Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, This trial is looking at treating pancreatic cancer that has spread to another part of the body with pembrolizumab and olaparib.
hoz vg4 dft6w 8dpnh mo6w rv hvp53w sfij ea4xqzq gti